Fate Therapeutics' Leadership Changes
This article was originally published in Scrip
Fate Therapeutics has appointed Scott Wolchko president and CEO following Christian Weyer's resignation – effective Nov. 30, 2015. Wolchko, who was chief financial officer (CFO) since the company was found in 2007 and chief operating officer since January 2013, has also joined Fate's board of directors. Prior to Fate, Wolchko was CFO of an enterprise software company, Bocada Inc. In addition to Wolchko's appointment, Dr. Daniel Shoemaker has been promoted to chief scientific officer from chief technology officer; Dr. Stewart Abbot, formerly vice-president of translational research, has been named chief development officer; and Cindy Tahl has been promoted to general counsel after being the company's senior legal counsel since 2009.